Europe Cancer Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Europe Cancer Biological Therapy Market Growth and the market is segmented into By Treatment Type (Chemotherapy, Target Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Other Treatment Types), Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, Other Cancer Types), By End-Users (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers), and Geography (Germany, United Kingdom, France, Italy, Spain, Rest of Europe). The market provides the value (in USD million) for the above-mentioned segments.

Europe Cancer Therapeutics Market Size

European Cancer Therapies Market Industry Summary

Europe Cancer Therapeutics Market Analysis

The Europe Cancer Therapeutics Market size is estimated at USD 61.46 billion in 2025, and is expected to reach USD 79.87 billion by 2030, at a CAGR of 5.38% during the forecast period (2025-2030).

At the start of the global spread of COVID-19 in early 2020, patients with cancer were designated as a particularly vulnerable subgroup of the population. Cancer patients have been reported to be both at increased risk of contracting SARS-CoV-2 infection and of running a more severe disease course, with a higher proportion requiring greater levels of intensive care, having a more rapidly evolving disease, and an increased risk of death. Additionally, it seems that cancer treatment does not associate with COVID-19 severity, which could help cancer patient's well-being during this pandemic. The consequences of this pandemic for the cancer therapeutics market seemed to be heavy, as the entire healthcare system got reorganized.

The driving factors for the growth of the European cancer therapeutics market include the ease in regulatory approval for novel cancer therapy in Europe, the rising prevalence of cancer, and strong R&D investments by the key players in the region. According to the International Agency for the Research on Cancer, 2021 data reported that the number incidence of cancer cases for the European region in the year 2020 was 4.79 million cancer cases and the number is expected to increase to 6.07 million by 2040. Thus, increasing the incidence of cancer cases is more likely to drive the market.

In addition, the heavy investments made in R&D activities have enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and recent mergers, acquisitions, and launches within the key market players have also boosted the growth of the market. For instance, in May 2020 Boehringer Ingelheim acquired Northern Biologics, a wholly owned subsidiary of Northern LP. This acquisition has assisted the company to add two complementary assets to its existing cancer immunology portfolio including cancer vaccines, oncolytic viruses, T-cell engagers, and myeloid cell modulators.

Thus, due to the aforesaid mentioned reasons the company is expected to show significant growth over the forecast period, however high cost of cancer therapies, and inequality in access to cancer therapy across Europe may slow down the growth of the market.

Europe Cancer Therapeutics Industry Overview

The Europe cancer therapeutics market is fragmented in nature due to the presence of fewer companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known as Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis AG, and Pfizer Inc.

Europe Cancer Therapeutics Market Leaders

  1. Amgen Inc.

  2. AstraZeneca PLC

  3. Bayer AG

  4. Bristol-Meyrs Squibb Company

  5. F. Hoffmann-La Roche Ltd

  6. *Disclaimer: Major Players sorted in no particular order
European Cancer Therapies Market Industry Concentration
Need More Details on Market Players and Competiters?
Download PDF

Europe Cancer Therapeutics Market News

  • In May 2022 Boehringer Ingelheim acquired Northern Biologics, a wholly owned subsidiary of Northern LP. This acquisition has assisted the company to add two complementary assets to its existing cancer immunology portfolio including cancer vaccines, oncolytic viruses, T-cell engagers, and myeloid cell modulators.
  • In June 2021, Genetech collaborated with Nykode (Vaccibody) to develop novel DNA-based cancer vaccines. This global, oncology collaboration between Nykode and Genentech is to develop individualized neoantigen cancer vaccines across multiple tumor types.

Europe Cancer Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Cancer in Europe
    • 4.2.2 Strong R&D Initiatives from Key Players
  • 4.3 Market Restraints
    • 4.3.1 Inequality in Access of Cancer Therapy across Europe
    • 4.3.2 High Cost of Cancer Therapies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Treatment
    • 5.1.1 Chemotherapy
    • 5.1.2 Target Therapy
    • 5.1.3 Immunotherapy (Biologic Therapy)
    • 5.1.4 Hormonal Therapy
    • 5.1.5 Other Treatment Types
  • 5.2 By Cancer Type
    • 5.2.1 Blood Cancer
    • 5.2.2 Breast Cancer
    • 5.2.3 Prostate Cancer
    • 5.2.4 Gastrointestinal Cancer
    • 5.2.5 Gynecologic Cancer
    • 5.2.6 Respiratory/Lung Cancer
    • 5.2.7 Other Cancer Types
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Specilty Clinics
    • 5.3.3 Cancer and Radiation Therapy Centers
  • 5.4 By Geography
    • 5.4.1 Germany
    • 5.4.2 United Kingdom
    • 5.4.3 France
    • 5.4.4 Italy
    • 5.4.5 Spain
    • 5.4.6 Rest of Europe

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca PLC
    • 6.1.3 Bayer AG
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 Pfizer Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Cancer Therapeutics Industry Segmentation

As per the scope of the report, Europe cancer therapeutics are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. The cancer therapeutics market is segmented by Treatment Type (Chemotherapy, Target Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Other Treatment Types), Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, Other Cancer Types), By End-Users (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers, and Geography (Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe)). The report offers the value (in USD million) for the above segments.

By Treatment Chemotherapy
Target Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Other Treatment Types
By Cancer Type Blood Cancer
Breast Cancer
Prostate Cancer
Gastrointestinal Cancer
Gynecologic Cancer
Respiratory/Lung Cancer
Other Cancer Types
By End User Hospitals
Specilty Clinics
Cancer and Radiation Therapy Centers
By Geography Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Cancer Therapeutics Market Research FAQs

How big is the Europe Cancer Therapeutics Market?

The Europe Cancer Therapeutics Market size is expected to reach USD 61.46 billion in 2025 and grow at a CAGR of 5.38% to reach USD 79.87 billion by 2030.

What is the current Europe Cancer Therapeutics Market size?

In 2025, the Europe Cancer Therapeutics Market size is expected to reach USD 61.46 billion.

Who are the key players in Europe Cancer Therapeutics Market?

Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Meyrs Squibb Company and F. Hoffmann-La Roche Ltd are the major companies operating in the Europe Cancer Therapeutics Market.

What years does this Europe Cancer Therapeutics Market cover, and what was the market size in 2024?

In 2024, the Europe Cancer Therapeutics Market size was estimated at USD 58.15 billion. The report covers the Europe Cancer Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Cancer Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Europe Cancer Therapeutics Industry Report

Statistics for the 2025 Europe Cancer Therapeutics market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Europe Cancer Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Europe Cancer Therapeutics Market Report Snapshots

Compare market size and growth of Europe Cancer Therapeutics Market with other markets in Healthcare Industry

Europe Cancer Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)